Supernus Pharma (SUPN) Misses Q3 EPS by 31c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of ($0.29), $0.31 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $153.88 million versus the consensus estimate of $144.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand